Using Evidence to Improve Population Health

An endowed operating foundation that works to improve the health of populations by connecting leaders and decision makers with the best available evidence and experience

What’s New

  • We’ll See You at the AcademyHealth Annual Research Meeting

    Jun 20, 2017

    If you are attending the AcademyHealth Annual Research Meeting from June 25 to 27 in New Orleans, look for us. Howard Markel, editor-in-chief of The Milbank Quarterly, will speak on the panel, “Publishing Instead of Perishing: Meet the Editors, Part Two,” on Monday, June 26, from 11:15 am to 12:45 pm. Christopher Koller, president of the Milbank Memorial Fund, and Tara Strome, assistant … Read more

Blog: The View from Here

  • Total Health Care Spending by State: Wide Variations in Amounts and Trends

    Jun 20, 2017 | Christopher F. Koller, President

    The game of hot potato ends one of two ways—someone drops the potato as it is being tossed or it finally cools off.  But what happens if the potato stays hot? How long can you get everybody to keep playing catch?  How do you get it to cool off? We are playing hot potato with health care costs in the United States—shifting them to whomever we can. Some new analyses on health care spending … Read more

  • Featured Article

    Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval

    Huseyin Naci, Olivier J. Wouters, Radhika Gupta, John P.A. Ioannidis

    What is the clinical evidence on therapeutic agents that treat serious conditions and are eligible for Food and Drug Administration accelerated approval? This study is the first to provide a systematic evaluation of the evidence on drugs receiving this type of approval between 2000 and 2013. These drugs often quickly become part of standard treatment, despite shortcomings in their evidence base. Read more

  • Consumer Perspectives on Access to Direct-to-Consumer Genetic Testing: Role of Demographic Factors and the Testing Experience

    Sarah E. Gollust, Stacy W. Gray, Deanna Alexis Carere, Barbara A. Koenig, Lisa Soleymani Lehmann, Amy L. McGuire, Richard R. Sharp, Kayte Spector-Bagdady, Na Wang, Robert C. Green, J. Scott Roberts, for the PGEN Study Group

    In mid-April, 23andMe received FDA approval to sell tests for 10 genetic conditions. As the New York Times reported in May, the tests are now creating problems for insurers who have no way of knowing the results. Researchers found that the majority of consumers supported expanded access to genetic testing services and oppose additional regulation, while those who had a negative experience were less supportive of expanded availability without a medical professional. Read more

View the current issue of the Quarterly

Latest Fund Resources